These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 11251172)

  • 1. The anti-malarial artesunate is also active against cancer.
    Efferth T; Dunstan H; Sauerbrey A; Miyachi H; Chitambar CR
    Int J Oncol; 2001 Apr; 18(4):767-73. PubMed ID: 11251172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of artesunate on cytokinesis and G₂/M cell cycle progression of tumour cells and budding yeast.
    Steinbrück L; Pereira G; Efferth T
    Cancer Genomics Proteomics; 2010; 7(6):337-46. PubMed ID: 21156967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells.
    Efferth T; Giaisi M; Merling A; Krammer PH; Li-Weber M
    PLoS One; 2007 Aug; 2(8):e693. PubMed ID: 17668070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular modes of action of artesunate in tumor cell lines.
    Efferth T; Sauerbrey A; Olbrich A; Gebhart E; Rauch P; Weber HO; Hengstler JG; Halatsch ME; Volm M; Tew KD; Ross DD; Funk JO
    Mol Pharmacol; 2003 Aug; 64(2):382-94. PubMed ID: 12869643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mRNA expression profiles for the response of human tumor cell lines to the antimalarial drugs artesunate, arteether, and artemether.
    Efferth T; Olbrich A; Bauer R
    Biochem Pharmacol; 2002 Aug; 64(4):617-23. PubMed ID: 12167480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Willmar Schwabe Award 2006: antiplasmodial and antitumor activity of artemisinin--from bench to bedside.
    Efferth T
    Planta Med; 2007 Apr; 73(4):299-309. PubMed ID: 17354163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination treatment of glioblastoma multiforme cell lines with the anti-malarial artesunate and the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774.
    Efferth T; Ramirez T; Gebhart E; Halatsch ME
    Biochem Pharmacol; 2004 May; 67(9):1689-700. PubMed ID: 15081868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1.
    Chen HH; Zhou HJ; Wu GD; Lou XE
    Pharmacology; 2004 May; 71(1):1-9. PubMed ID: 15051917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Artesunate exerts specific cytotoxicity in retinoblastoma cells via CD71.
    Zhao F; Wang H; Kunda P; Chen X; Liu QL; Liu T
    Oncol Rep; 2013 Sep; 30(3):1473-82. PubMed ID: 23818062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Artesunate reduces chicken chorioallantoic membrane neovascularisation and exhibits antiangiogenic and apoptotic activity on human microvascular dermal endothelial cell.
    Huan-huan C; Li-Li Y; Shang-Bin L
    Cancer Lett; 2004 Aug; 211(2):163-73. PubMed ID: 15219940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The anti-malarial drug artesunate causes cell cycle arrest and apoptosis of triple-negative MDA-MB-468 and HER2-enriched SK-BR-3 breast cancer cells.
    Greenshields AL; Fernando W; Hoskin DW
    Exp Mol Pathol; 2019 Apr; 107():10-22. PubMed ID: 30660598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanistic perspectives for 1,2,4-trioxanes in anti-cancer therapy.
    Efferth T
    Drug Resist Updat; 2005; 8(1-2):85-97. PubMed ID: 15878303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of reactive oxygen species to ovarian cancer cell growth arrest and killing by the anti-malarial drug artesunate.
    Greenshields AL; Shepherd TG; Hoskin DW
    Mol Carcinog; 2017 Jan; 56(1):75-93. PubMed ID: 26878598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-level artemisinin-resistance with quinine co-resistance emerges in P. falciparum malaria under in vivo artesunate pressure.
    Tyagi RK; Gleeson PJ; Arnold L; Tahar R; Prieur E; Decosterd L; Pérignon JL; Olliaro P; Druilhe P
    BMC Med; 2018 Oct; 16(1):181. PubMed ID: 30269689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis.
    Jeong DE; Song HJ; Lim S; Lee SJ; Lim JE; Nam DH; Joo KM; Jeong BC; Jeon SS; Choi HY; Lee HW
    Oncotarget; 2015 Oct; 6(32):33046-64. PubMed ID: 26426994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors determining sensitivity or resistance of tumor cell lines towards artesunate.
    Sertel S; Eichhorn T; Sieber S; Sauer A; Weiss J; Plinkert PK; Efferth T
    Chem Biol Interact; 2010 Apr; 185(1):42-52. PubMed ID: 20144594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergism of cytotoxicity effects of triptolide and artesunate combination treatment in pancreatic cancer cell lines.
    Liu Y; Cui YF
    Asian Pac J Cancer Prev; 2013; 14(9):5243-8. PubMed ID: 24175808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Considerations on the mechanism of action of artemisinin antimalarials: part 1--the 'carbon radical' and 'heme' hypotheses.
    Haynes RK; Cheu KW; N'Da D; Coghi P; Monti D
    Infect Disord Drug Targets; 2013 Aug; 13(4):217-77. PubMed ID: 24304352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasmodium vivax and Plasmodium falciparum ex vivo susceptibility to anti-malarials and gene characterization in Rondônia, West Amazon, Brazil.
    Aguiar AC; Pereira DB; Amaral NS; De Marco L; Krettli AU
    Malar J; 2014 Feb; 13():73. PubMed ID: 24581308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Artesunate in the treatment of metastatic uveal melanoma--first experiences.
    Berger TG; Dieckmann D; Efferth T; Schultz ES; Funk JO; Baur A; Schuler G
    Oncol Rep; 2005 Dec; 14(6):1599-603. PubMed ID: 16273263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.